Follow-up of localized prostate cancer, with emphasis on previous undiagnosed incidental cancer

BJU International

Volumn 83, Issue 1, 1999, Pages 47-52

  Berner, A ^a   Harvei, S ^b   Skjorten F J ^c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b CANCER REGISTRY OF NORWAY   (Norway)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Biology; Follow up; Incidental; Localized; Natural history; Prostate cancer

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER REGISTRY; CANCER SURVIVAL; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; NORWAY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER;

EID: 0033034143     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.1999.00896.x     Document Type: Article

References (37)

1. 1 Scardino PT, Weaver R, Hudson MA. Early detection of prostate cancer. Hum Pathol 1992; 23: 211-22
2. 2 McNeal JE, Price H, Redwine EA, Stamey TA. Stage A versus stage B adenocarcinoma of the prostate: morphologic comparison and biologic significance. J Urol 1988; 139: 61-8
3. 3 McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma: correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988b; 12: 897-906
4. 4 Epstein JI, Oesterling JE, Walsh PC. The volume and anatomic location of residual tumor in radical prostatectomy specimens removed for stage A1 prostate cancer. J Urol 1988; 139: 975-9
5. 5 Voges GE, McNeal JE, Redwine EA, Freiha FS, Stamey TA. The predictive significance of substaging stage A prostate cancer (A1 versus A2) for volume and grade of total cancer in the prostate. J Urol 1992; 147: 858-63
6. 6 Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittmore AS, Schmid H-P. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993; 71: 933-8
7. 7 Skjørten FJ, Berner A, Harvei S, Robsahm TE, Tretli S. Prostatic intraepithelial neoplasia (PIN) in surgical resections: relationship to coexistent adenocarcinoma and atypical adenomatous hyperplasia of the prostate. Cancer 1997; 79: 1172-9
8. 8 Harvei S, Tretli S, Langmark F. Quality of prostate cancer data in the Cancer Registry of Norway. Eur J Cancer 1996; 32: 104-10
9. 9 Greenwood M. Reports on public health and medical subjects. no. 33, Appendix 1: The Errors of Sampling of the Survivorship Tables. London HM Statistics Office, 1926
10. 10 Smart CR. The results of prostate carcinoma screening in the U.S. as reflected in the surveillance, epidemiology, and end results program. Cancer 1997; 80: 1835-44
11. 11 Bostwick DG, Choi C. Prognostic factors in early prostate cancer. Urol Ann 1992; 6: 63-101
12. 12 Greene DR, Wheeler TM, Egawa S, Dunn JK, Scardino TP. A comparison of the morphologic features of cancer arising in the transition zone and in the peripheral zone of the prostate. J Urol 1991; 146: 1069-76
13. 13 Blute ML, Zincke H, Farrow GM. Long-term followup of young patients with stage A adenocarcinoma of the prostate. J Urol 1986; 136: 840-3
14. 14 Cantrell BB, DeKlerk DP, Eggleston JC, Boitnott JK, Walsh PC. Pathological factors that influence prognosis in stage A prostate cancer: the influence of extent versus grade. J Urol 1981; 125: 516-20
15. 15 Epstein JI, Gerson P, Eggleston JC, Walsh PC. Prognosis of untreated stage A1 prostatic carcinoma: a study of 94 cases with extended followup. J Urol 1986; 136: 837-9
16. 16 Lowe BA, Listrom MB. Incidental carcinoma of the prostate: an analysis of the predictors of progression. J Urol 1988; 140: 1340-4
17. 17 Zhang G, Wassermann NF, Sidi AA, reinberg Y, Reddy PK. Long-term follow-up results after expectant management of stage A1 prostatic cancer. J Urol 1991; 146: 99-103
18. 18 Larsen MP, Carter HB, Epstein JI. Can stage A1 tumor extent be predicted by transurethral resection tumor volume, per cent or grade? A study of 64 stage A1 radical prostatectomies with comparison to prostates removed for stages A2 and B disease. J Urol 1991; 146: 1059-63
19. 19 Johansson J-E, Andersson S-O, Krusemo UB, Adami H-O, Bergstrom R, Kraaz W. Natural history of localised prostatic cancer. A population-based study in 223 untreated patients. Lancet 1989; 6: 789-803
20. 20 Johansson J-E, Adami H-O, Andersson S-O, Bergstrom R, Holmberg L, Krusemo UB. High 10 year survival rate in patients with early, untreated prostatic cancer. JAMA 1992; 267: 2191-6
21. 21 Barnes R, Hirst A, Rosenquist R. Early carcinoma of the prostate: comparison of stage A and B. J Urol 1976; 115: 404-5
22. 22 George NJR. Natural history of localised prostatic cancer managed by conservative therapy alone. Lancet 1988; 5: 494-7
23. 23 Adolfsson J, Steineck G, Whitmore WF. Recent results of management of palpable clinically localized prostate cancer. Cancer 1993; 72: 310-22
24. 24 Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995; 274: 626-31
25. 25 Whitmore WF, Warner JA, Thompson IM. Expectant management of localized prostatic cancer. Cancer 1991; 67: 1091-6
26. 26 Graversen PH, Nielsen KT, Gasser TG, Corle DK, Madsen PO. Radical prostatectomy versus expectant primary treatment in stages I and II prostatic cancer. A fifteen year follow-up. Urology 1990; 36: 493-8
27. 27 Thompson IM. Observation alone in the management of localised prostate cancer: the natural history of untreated disease. Urology 1994; 43: 41-46
28. 28 Borre M, Nerstrom B, Overgaard J. The natural history of prostate carcinoma based on a Danish population treated with no intent to cure. Cancer 1997; 80: 917-28
29. 29 Johansson J-E. Expectant management of early stage prostatic cancer: Swedish experience. J Urol 1994; 152: 1753-6
30. 30 Chodak GW, Thisted RA, Gerber GS et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994; 330: 242-8
31. 31 Berner A, Harvei S, Tretli S, Fosså SD, Nesland JM. Prostatic carcinoma: a multivariate analysis of prognostic factors. Br J Cancer 1994; 69: 924-30
32. 32 Kant AK, Glover C, Horm J, Schatzkin A, Harris TB. Does survival differ for older patients? Cancer 1992; 70: 2734-40
33. 33 Partin AW, Steinberg GD, Pitcock RV et al. Use of nuclear morphometry, Gleason histologic scoring, clinical stage, and age to predict disease-free survival among patients with prostate cancer. Cancer 1992; 70: 161-8
34. 34 Zagars GK, von Eschenbach AC, Ayala AG. Prognostic factors in prostate cancer. Cancer 1993; 72: 1709-25
35. 35 Albertsen PC, Fryback DG, Storer BE, Kolon TF. Fine j: The impact of comorbidity on life expectancy among men with localized prostate cancer. J Urol 1996; 156: 127-32
36. 36 Murphy WM, Dean PJ, Brasfield JA, Tatum L. Incidental carcinoma of the prostate. How much sampling is adequate? Am J Surg Pathol 1986; 10: 170-4
37. 37 McDowell PR, Fox WM, Epstein JI. Is submission of remaining tissue necessary when incidental carcinoma of the prostate is found on transurethral resection? Hum Pathol 1994; 25: 493-7